Spain Cancer Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Spain · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$161.7 MnPlaceholder estimate
Estimate 2025$178.1 Mn2.1% of the global market
Projected 2034$423.3 Mn 137.7%Adds $245.3 Mn over 9 forecast years
CAGR 2025–203410.1%Faster than 65% of 180 Pharmaceuticals markets here
11 in SpainSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Spain Cancer Vaccines Market Analysis Executive Summary
Cancer vaccines train the immune system to recognise and attack cancer, including personalised mRNA vaccines and preventive vaccines.
Key segments of the cancer Vaccines market include type (Personalized Neoantigen Vaccines, Preventive Vaccines and Dendritic Cell Vaccines) and indication (Melanoma, Lung Cancer and Prostate Cancer).
Spain Cancer Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Spain Cancer Vaccines Market Dynamics
Market Growth Drivers
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Vaccines market. Faster approvals and new combinations are improving survival.
Opportunity
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the cancer Vaccines market.
Market Restraints
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the cancer Vaccines market, especially in low- and middle-income countries.
Competitive Landscape for Cancer Vaccines Market in Spain
The cancer Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Cancer Vaccines Market in Spain
Cancer Vaccines in Spain: rules, payment and research
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AEMPS, the Spanish Agency of Medicines and Medical Devices.[1] The National Health System (SNS), run by the regions, gives universal public care.[2] ClinicalTrials.gov lists 11 studies on Cancer Vaccines that are recruiting, active or about to start in Spain.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cancer Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Spain.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Moderna
7.2 Merck & Co.
7.3 BioNTech
7.4 Dendreon
7.5 Gritstone bio
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The cancer Vaccines market can be segmented based on various criteria, including type, indication and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Cancer Vaccines right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Cancer Vaccines in context
Spain compared
Health spending per person: 3,107 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 6 countries we cover in Europe.[1]
Doctors: 4.29 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 6 countries we cover in Europe.[2]
People aged 65 and over: 21.6% of people (2025). World: 10.4% of people (2025). 4th highest of the 6 countries we cover in Europe.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
Placeholder estimate: about $178.1 Mn in 2025, rising to about $423.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Cancer Vaccines market in Spain growing?
Placeholder estimate: about 10.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Cancer Vaccines market report cover?
The report splits the market by type (Personalized Neoantigen Vaccines, Preventive Vaccines, Dendritic Cell Vaccines, Viral Vector Vaccines), indication (Melanoma, Lung Cancer, Prostate Cancer, Cervical Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Cancer Vaccines market?
Key players include Moderna, Merck & Co., Inc., BioNTech, Dendreon Pharmaceuticals LLC and Gritstone bio.
What is driving the Cancer Vaccines market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Vaccines market. Faster approvals and new combinations are improving survival.
Who regulates Cancer Vaccines in Spain?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AEMPS, the Spanish Agency of Medicines and Medical Devices. Source: Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
How is healthcare paid for in Spain?
The National Health System (SNS), run by the regions, gives universal public care. Source: Spanish Ministry of Health. Checked 14 Nov 2026.
How many clinical trials on Cancer Vaccines are running in Spain?
11 studies are recruiting, active or about to start in Spain, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.
How much research is published on Cancer Vaccines?
PubMed lists 2,635 papers on Cancer Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.